2020
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2020, 87: e338-e346. PMID: 32315434, PMCID: PMC7534487, DOI: 10.1093/neuros/nyaa071.Peer-Reviewed Original ResearchConceptsKarnofsky performance scorePrimary tumorBaseline Karnofsky performance scoreCancer Therapy-BrainPostprocedure hospital stayReal-world registryPatient-reported QOLNeurological tissuesHigh-grade gliomasQuality of lifeReal-world outcomesBaseline comorbiditiesHospital stayAdverse eventsMost patientsOverall survivalMedian ageBrain tumor ablationRadiation necrosisPatient populationMetastatic cancerFunctional assessmentSurvival rateBaseline levelsQoL
2017
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal Of Radiation Oncology • Biology • Physics 2017, 99: 812-816. PMID: 29063850, PMCID: PMC6925529, DOI: 10.1016/j.ijrobp.2017.06.2454.Peer-Reviewed Original ResearchConceptsDiagnosis-Specific Graded Prognostic AssessmentGraded Prognostic AssessmentSignificant prognostic factorsBrain metastasesMelanoma-molGPAPrognostic factorsMelanoma patientsPrognostic assessmentMultiple Cox regressionMedian survival timeRetrospective database analysisLog-rank testHeterogeneous patient populationClinical decision makingTreatment eraHazard ratioMedian survivalMultivariable analysisWorse prognosisCox regressionPatient populationSurvival timePatientsMetastasisCurrent cohort
2016
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell & Melanoma Research 2016, 29: 627-642. PMID: 27615400, PMCID: PMC5398760, DOI: 10.1111/pcmr.12538.Peer-Reviewed Original Research
2006
Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases
DiLuna ML, King JT, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 2006, 109: 135-145. PMID: 17133440, DOI: 10.1002/cncr.22367.Peer-Reviewed Original ResearchConceptsSubgroup of patientsStereotactic radiosurgeryBreast cancerGamma Knife stereotactic radiosurgeryNonsmall cell lung carcinomaCommon tumor histologyInitial stereotactic radiosurgeryWhole brain radiationConnecticut Tumor RegistryMultivariate survival analysisTotal tumor volumeCell lung carcinomaBrain metastasesCerebral metastasesMedian survivalMetastasis locationMedian agePrognostic factorsTumor RegistryTumor histologyIntracranial metastasesPatient populationEsophageal cancerIndependent associationLung carcinoma